Impact of Metformin on Cognition Impairment in Type 2 Diabetic Male Albino Rats | ||||
| SVU-International Journal of Medical Sciences | ||||
| Article 42, Volume 7, Issue 2, July 2024, Page 451-467 PDF (1.25 MB) | ||||
| Document Type: Original research articles | ||||
| DOI: 10.21608/svuijm.2024.305735.1936 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mennatallah M. Bahgat  1; Ashraf Taye2; Esam Omar Kamel3; Abdulhakim Erian Mustafa Wazeery4; Sahar Marei Zaki5; Abeer Madkour Mahmoud6; Reham A.M. Ellisy1
| ||||
| 1Medical Pharmacology Department, Faculty of Medicine, South Valley University, Qena, Egypt. | ||||
| 2Pharmacology and Toxicology Department, Faculty of Pharmacy, South Valley University, Qena, Egypt. | ||||
| 3Department of Histology and Cell Biology Al-Azhar University, Assiut Branch, Assiut, Egypt. | ||||
| 4Internal Medicine Department, Faculty of Medicine, South Valley University, Qena, Egypt. | ||||
| 5Medical Physiology Department, Faculty of Medicine, Luxor University, Luxor, Egypt. | ||||
| 6Human Anatomy and Embryology Department, Faculty of Medicine, South Valley University, Qena, Egypt. | ||||
| Abstract | ||||
| Background: There is controversy around metformin benefits, an insulin-sensitizing drug that is frequently administered, for enhancing cognitive performance in type 2 diabetic mellitus (T2DM) patients which increases cognitive impairment risk. Objectives: This study aims to assess the ameliorative effects of metformin on T2DM-induced cognitive impairment. Materials and methods: Rats were randomly assigned to three groups: group I (Control), group II (Diabetic), and group III (Diabetic-Metformin). Streptozotocin (STZ) (30 mg/kg, i.p.) administered as single dose to groups II and III following ten-week high-fat diet. Group III received metformin for ten weeks. Hippocampal memory examined using T Maze and novel object cognition tests were performed before animal scarification. Hippocampal samples were extracted at experiment end for biochemical (TNFα, IL-1β levels), histological and immunohistochemical (Bcl2/Bax ratio) studies. Results: Group III showed a significant increase in spontaneous alternation in T-maze test (76.67% ± 15.02) compared to group II (6.67% ± 10.32) (p < 0.001). Significant increase in discrimination ratio in novel object recognition test was observed in group III after treatment (0.111 ± 0.02) compared to before treatment (-0.0466 ± 0.015) (P < 0.05). There was increase in Bcl-2/Bax ratio expression (2.794 ± 0.59) after treatment compared to before treatment (0.294 ± 0.08) (P < 0.001). Metformin decreased levels of TNFα and IL-1β in diabetic rats from (753.2 ± 86.3), (455.7 ± 43.6) respectively, to (372.1 ± 48.1), (220.1 ± 16.3) (P < 0.001). Conclusion: Our results suggest that metformin may be promising drug for improving T2DM-induced cognitive dysfunction by reducing harmful pathophysiological effects. | ||||
| Keywords | ||||
| T2DM; Apoptosis; Inflammation; Metformin; Cognition impairment; BCL2/BAX ratio | ||||
|
Statistics Article View: 227 PDF Download: 141 |
||||
